Mon.May 13, 2024

article thumbnail

CDC launching wastewater dashboard to track bird flu virus spread

STAT

Reluctance among dairy farmers to report H5N1 bird flu outbreaks within their herds or allow testing of their workers has made it difficult to keep up with the virus’s rapid spread , prompting federal public health officials to look to wastewater to help fill in the gaps. On Monday, the Centers for Disease Control and Prevention is expected to unveil a public dashboard tracking influenza A viruses in sewage that the agency has been collecting from 600 wastewater treatment sites around the

364
364
article thumbnail

5 trends impacting drug spend in the U.S.

PharmaVoice

Key factors changing how much Americans spend on prescriptions.

268
268
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Opinion: A dose of reality on adult vaccinations

STAT

The number of children who received their routine vaccinations declined during the pandemic, so public health officials have been focusing on getting kids back up to date. They should also be paying attention to adults as a new, first-of-its-kind report quantifying the economic impact of adult immunizations makes clear. Researchers at the nonprofit Office of Health Economics , based in London, analyzed four adult vaccine programs — for the flu, pneumonia, respiratory syncytial virus (RSV)

Vaccines 363
article thumbnail

PEM POCUS Series: Soft Tissue Ultrasound

ALiEM - Pharm Pearls

Read this tutorial on the use of point of care ultrasonography (POCUS) for pediatric soft tissue ultrasonography. Then test your skills on the ALiEMU course page to receive your PEM POCUS badge worth 2 hours of ALiEMU course credit. Take the ALiEMU PEM POCUS: Soft Tissue Quiz Case Goals List the indications of performing a pediatric soft tissue point-of-care ultrasound (POCUS).

article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

After decades fighting Big Tobacco, Cliff Douglas now leads a foundation funded by his former adversaries

STAT

“Does it trouble you to answer that question?” one of New York’s highest paid attorneys asked Cliff Douglas, then a 36-year-old activist who had found himself at the center of a $10 billion libel lawsuit brought by the cigarette giant Philip Morris. Philip Morris’ lawyer Herbert Wachtell demanded to know: Were cigarette companies intentionally killing people?

361
361
article thumbnail

Thinking inside the box: How SmartLabs is transforming laboratories for modern science and accelerating innovation

PharmaVoice

SmartLabs offers the first integrated platform combining re-configurable lab infrastructure, operations and scientific expertise.

130
130

More Trending

article thumbnail

Biosimilars are gaining ground. The IRA could push them even further next year.

PharmaVoice

As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.

article thumbnail

STAT+: FDA is criticized for taking a ‘ministerial’ role in sorting out some pharma patents

STAT

When it comes to a crucial controversy over pharmaceutical patents, the FDA has been MIA. For nearly 20 years, drug companies have asked the Food and Drug Administration for guidance on listing patents for drug-and-device combination products, such as asthma inhalers and auto-injectors for diabetes treatments, in an obscure, but highly important agency registry.

Diabetes 354
article thumbnail

Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot

pharmaphorum

Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy. The option fee could be followed by another up to $2.1 billion in potential milestones if Takeda takes global rights to the programme, currently headed by ACI-24.060 which is in a phase 1b/2 trial with new data due in the next few weeks.

article thumbnail

Genetic variant common among West African descendants contributes to large cardiovascular disease burden

STAT

Among cardiologists, it’s known that transthyretin cardiac amyloidosis, a type of heart disease, is caused by the misfolding of a protein called transthyretin, which builds up in the walls of the heart, causing the muscle to get thicker and stiffer. One reason this can happen is because of a genetic mutation caused by the gene variant V142I, which is commonly found in people of West African descent.

Hospitals 318
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Ajax, aiming for a better JAK drug, raises $95M to begin first tests

BioPharma Dive

Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.

131
131
article thumbnail

STAT+: Late-stage results set up Cytokinetics heart drug to compete with Bristol

STAT

Late-stage results of Cytokinetics’ drug for a rare heart disease suggest it can compete with a similar treatment sold by Bristol Myers Squibb on efficacy and safety, and can also be dosed more conveniently, potentially making it a more attractive option for doctors if approved. The 24-week Phase 3 trial tested the drug, a daily pill called aficamten, in patients with obstructive hypertrophic cardiomyopathy, or oHCM, a disease in which the heart has more difficulty pumping blood and patie

347
347
article thumbnail

Transforming clinical trials with open-source tech

pharmaphorum

Think open-source is just for software? Think again. Learn how clinical researchers are embracing open data and tools to overhaul the drug development process.

article thumbnail

STAT+: The stories that shaped our understanding of the health care system

STAT

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. We did something a little different for this issue: We wanted to share some of the stories that explain the machinations of the U.S. health care system — stories that really influenced how we think about and report on this industry.

Hospitals 342
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

BREAKING: Government publishes hub and spoke consultation response

The Pharmacist

Hub and spoke dispensing between pharmacies owned by different legal entities will be allowed from 1 January 2025, subject to parliamentary approval, the government has announced. In its consultation response published today, the government proposed introducing two models of hub and spoke dispensing across legal entities. In one model the hub would directly supply the […] The post BREAKING: Government publishes hub and spoke consultation response appeared first on The Pharmacist.

126
126
article thumbnail

STAT+: Sandoz disavows U.K. trade group over dispute about promoting a biosimilar for multiple sclerosis

STAT

In an unusual move, Sandoz is no longer cooperating with a U.K. industry trade group following a dispute over allegations that the company inappropriately marketed a biosimilar medicine. At issue was an anonymous complaint filed in May 2023 by a physician who contended that Sandoz unfairly attempted to promote a biosimilar version of Tysabri for treating multiple sclerosis as an affordable option.

article thumbnail

Is digital therapeutics innovation enough for a sustainable future?

pharmaphorum

Digital therapeutics are transforming healthcare, but are they enough for a sustainable future? This post discusses whether innovation in digital therapeutics that empower patients is sufficient for long-term sustainability.

112
112
article thumbnail

We now know Tome’s gene editing target

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello! Today we learn whether AI might help hasten the development of n-of-1 therapies (hint: not yet), explore why the FDA hasn’t offered Orange Book guidance on drug-device combinations, and talk about CRISPR.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Who delays NICE technology appraisals anyway?

pharmaphorum

NICE technology appraisals for cancer drugs are often delayed - but who's really to blame? This post investigates how the DHSC contributes to hold-ups in access to innovative cancer treatments.

111
111
article thumbnail

STAT+: Pharmalittle: We’re reading about FDA dithering on pharma patents, WHO pandemic talks, and more

STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and inspiring, because that oh-too predictable routine of online meetings, phone calls, and deadlines has returned. But what can you do? The world, such as it is, continues to spin. So to give it a nudge in a better direction, we are firing up the coffee kettle to brew some cups of stimulation.

Diabetes 272
article thumbnail

When Worlds Collide: The Theory of Real-World Evidence Meets Reality

FDA Law Blog: Biosimilars

By Jeffrey N. Gibbs & Ana Loloei & Véronique Li, Senior Medical Device Regulation Expert — FDA has long touted the use of real-world evidence ( RWE ). Extolling RWE, FDA has said “RWE can be leveraged to bring new products to market, evaluate the safety and effectiveness of existing products for new uses, and assess the continued performance and safety of products once on the market.

article thumbnail

Melinda French Gates resigns as Gates Foundation co-chair

STAT

Melinda French Gates will step down as co-chair of the  Bill & Melinda Gates Foundation , the nonprofit she and her ex-husband Bill Gates founded and built into one of the world’s largest philanthropic organizations over the past 20 years. “This is not a decision I came to lightly,” French Gates posted on the X platform on Monday.

250
250
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Rise of drug-resistant superbugs could make Covid pandemic look ‘minor’, expert warns

The Guardian - Pharmaceutical Industry

Common infections will kill millions if drug resistance through misuse of antibiotics is not curbed, says England’s ex-chief medical officer What is antimicrobial resistance and how big a problem is it? The Covid-19 pandemic will “look minor” compared with what humanity faces from the growing number of superbugs resistant to current drugs, Prof Dame Sally Davies, England’s former chief medical officer, has warned.

111
111
article thumbnail

Too Much of a Good Thing? Unpacking the Rise of Polypharmacy in Seniors

PharmD Live

Introduction In an era marked by a rapidly aging population, the challenge of managing polypharmacy—the use of multiple medications by a patient, particularly among those over 65—has emerged as a pivotal issue for healthcare providers. For small independent clinics and larger health systems, addressing polypharmacy effectively is critical to optimizing patient outcomes, reducing risks, and ensuring financial sustainability.

article thumbnail

Sanofi to invest €1bn in France to lift ‘health sovereignty’

pharmaphorum

Sanofi will invest more than €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France as part of a €3.5 billion programme in the country. The latest tranche of investment – at Vitry-sur-Seine in Val de Marne, Le Trait in Seine-Maritime, and Lyon Gerland in the Rhône region – is part of a drive to reduce the reliance of France and the wider EU on manufacturing capacity in other parts of the world and boost supply chain security and resiliency.

105
105
article thumbnail

Impact of EU sustainability directive on supply chains

European Pharmaceutical Review

Eighty four percent of pharmaceutical and healthcare companies consider that the new EU Corporate Sustainability Due Diligence Directive (CSDDD) directive is an opportunity to “align human rights and environmental protection with their business objectives”, findings from a survey by supply chain specialist INVERTO has found. EU operations must comply with the new directive.

article thumbnail

Wearable device ‘may prevent heart failure hospitalisation’

pharmaphorum

Monitoring of heart failure patients at home using a wearable developed by ADI has shown in a new study that it may be able to reduce costly hospitalisations

109
109
article thumbnail

King Charles III announced as new RPS patron

The Pharmacist

His Majesty King Charles III has become the new patron of the Royal Pharmaceutical Society (RPS), it has been announced. The news marks the first anniversary of the Coronation of His Majesty and has been welcomed by the RPS which said it was ‘grateful to the Royal family for their ongoing support’. The late Queen […] The post King Charles III announced as new RPS patron appeared first on The Pharmacist.

104
104
article thumbnail

Sanofi's €1BN investment to enhance health sovereignty in France

Outsourcing Pharma

Sanofi, a global pharmaceutical giant, has announced a significant investment of over â1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France.

87
article thumbnail

MSD has another TIGIT programme setback

pharmaphorum

A phase 3 trial of MSD’s TIGIT antibody has been abandoned after a high rate of discontinuations rendered the study futile

110
110
article thumbnail

Novigenix collaborates with IMMUcan Consortium using AI platform to fight cancer

Outsourcing Pharma

Novigenix, a force in innovative cancer diagnostics, has announced a landmark partnership with the IMMUcan Consortium, a European leader in cancer research.

95
article thumbnail

Anticipation builds as Insmed bronchiectasis therapy brensocatib nears Phase III completion: GlobalData

Express Pharma

Insmed is in the spotlight over the past few years for its pipeline agent, brensocatib, which has previously shown promising Phase II results, generating anticipation within the medical community ahead of their Phase III results for the treatment of bronchiectasis. The positive outcomes could pave the way for regulatory approval, potentially transforming the therapeutic landscape for bronchiectasis, a disease that lacks the approval of any therapeutic treatment globally as of now.